
    
      The study is open and Infanrix hexa will serve as active control. Subjects will receive one
      vaccine dose of either Hib-MenC or Infanrix hexa, and will have 2 blood samples taken: before
      and one month after vaccination. Subjects who will receive a booster dose of Hib-MenC were
      primed with 3 doses of Infanrix penta + Hib-MenC or 2 doses of NeisVac-C and Infanrix hexa /
      Infanrix IPV/Hib.
    
  